Former televangelist Tammy Faye Messner -- formerly Tammy Faye Bakker -- posted Tuesday on her website (service is currently unavailable) a message about her health.

Messner, 65, reports that doctors have stopped treating her cancer -- she was diagnosed with colon cancer in 1996 and announced in 2004 the disease had spread to her lungs.

"I am down weight-wise to 65 pounds, and look like a scarecrow," the Charlotte resident shared on her site. "I need God's miracle to swallow. I look at young people and wish with all my heart for just one day of 'feeling great.'"

A clinical study involving 1,000 prostate cancer patients was stopped this week by Southwest Oncology Group in Michigan due to concerns the treatment may have caused leukemia in three of the participants.

The men in the study received the chemotherapy drug mitoxantrone, thought to possibly improve survival rates for those with poor prognoses following prostate surgery. But before results could be measured, leukemia struck and researchers halted the study, declaring the leukemia findings "an unacceptable risk to patients."

While the assumption is that the drug caused the leukemia -- a disease commonly associated with children and the elderly -- it's still unproved at this point.

Mitoxantrone is not a worthless drug, say some experts. Since its release a decade ago, it has been used to decrease bone pain for men with advanced prostate cancer and to treat multiple sclerosis and, ironically, adult leukemia.

Recent preliminary results from a Phase II clinical trial showed patients with recurrent glioblastoma multiforme, a form of primary brain cancer, experienced a significant tumor response rate with minimal side effects when treated with enzastaurin, an oral, targeted agent under development at Eli Lilly and Company.

On Thursday Eli Lilly & Co announced that it has stopped the Phase III trial of this experimental brain cancer drug. They determined that the treatment would not be any more effective than current chemotherapy treatments. The company said that it will still be evaluating enzastaurin as a potential treatment for non-Hodgkin's lymphoma. They will also be doing some trials that test the drug on other cancers, such as breast, colon, lung, ovarian and prostate.

Enzastaurin belongs to the families of drugs called protein kinase inhibitors and angiogenesis inhibitors.

I've been keeping a journal ever since I was first diagnosed with breast cancer. I first wrote by hand in a pink fabric-covered book, sprinkled with multi-colored polka dots. It looked feminine -- which is why I bought it -- and it's vibrance made me feel inspired, motivated, eager to write down the dreaded details of the beginning of my journey. Then I stopped writing in this book and began typing my words in an on-line journal -- a blog. My husband designed the presentation of it, with a pink banner that serves as the backdrop for the title -- my Breast Cancer blog. My first entry was completed on December 21, 2004 and I am still chronicling my journey here. I am also writing for this site -- the Cancer Blog -- and I write whenever and wherever else I can record my words. I do it because it helps me process information in a quiet, calming, introspective way. It soothes me, helps me work through panic and anxiety, helps me heal, and helps me chart my progress. When I look back at what I've written, I realize how far I've come -- or haven't come -- and it helps me move forward. I recommend journaling for everyone, and I recommend these seven simple suggestions for getting started.